Stay fully up to date in this fast-changing field with Hematology, Immunology and Genetics, 3rd Edition. The most current clinical information, including new coverage of exome sequencing, properties of donor milk, necrotizing enterocolitis and nutrition, thrombocytopenia in neonates with necrotizing ente...
June 3rd 2024 The safety profile of oral azacitadine was shown to be similar across the 200-mg and 300-mg arms in patients with lower- to intermediate-risk MDS. Tucidinostat/R-CHOP Combo Appears Effective, Safe in DLBCL Subtype Kristie L. Kahl ...
Cellular immunotherapy, particularly CAR-T cells, has shown potential in the improvement of outcomes in patients with refractory and recurrent malignancies of the blood. However, achieving sustainable long-term complete remission for blood cancer remains a challenge, with resistance and relapse being expe...
Primary and secondary screenings and systematic reviews were performed by persons in charge (SM/YN) of the working group of the Clinical Practice Guidelines for Tumor-Agnostic Genomic Medicine in Adult and Pediatric Patients with Advanced Solid Tumors (3rd edition). The recommendation levels specified...
Hoffman R, Benz EJ, Shattil S et al (2000) Hematology: basic principles and practice 3rd edition. Churchill Livingstone, London Google Scholar Leukemia & Lymphoma Research. Acute myeloid leukemia (AML). Patient information. Inhttps://leukaemialymphomaresearch.org.uk/2015. ...
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination t
Journal of Hematology & Oncology BioMed Central Review Open Access Recent advances of novel targeted therapy in non-small cell lung cancer Jed A Katzel, Michael P Fanucchi and Zujun Li* Address: Department of Hematology and Oncology, Saint Vincent's Hospital, Manhattan and New York Medical ...